References
- Rahaman M M., Khan M M., Aziz K MS, Islam M S., Kibriya A KMG. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal. I Infect Dis 1975; 132: 15–9
- Mata L J., Gangarosa E J., Caceres A, Perera D R., Mejicanos M L. Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969. J Infect Dis 1979; 122: 170–80
- Stoll B J., Glass R I., Huq M I., Khan M U., Banu H, Holt J. Epidemiologic and clinical features of patients infected with Shigella who attended a diarrhoeal disease hospital in Bangladesh. J Infect Dis 1982; 146: 177–83
- Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Aremye I H. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986; 29: 883–6
- Huppertz H I. An epidemic of bacillary dysentery in Western Rwanda 1981-1982. Cent Afr J Med 1986; 32: 79–82
- Murray B E. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8: S172–81
- Pal S C. Epidemic bacillary dysentery in West Bengal, India, 1984 [letter]. Lancet 1984; 1: 1462
- Bennish M, Eusof A, Kay B, Wierzba T. Multiresistant Shigella infections in Bangladesh [letter]. Lancet 1985; 2: 441
- Shahid N S., Rahaman M M., Haider K, Banu H, Rahman N. Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigellaflexneri in Bangladesh. J Infect Dis 1985; 152: 1114–9
- Salam M A., Bennish M L. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113: 901–7
- Munshi M H., Sack D A., Haider K, Ahmed Z U., Rahaman M M., Morshed M G. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987; 2: 419–21
- Bennish M L., Salam M A., Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162: 711–6
- Kabir I, Rahaman M M., Ahmed S M., Akhter S O. Butler T. Comparative efficacies of pivmecillinam and ampicillin in acute shigellosis. Antimicrob Agents Chemother 1984; 25: 643–5
- Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo controlled trial. Antimicrob Agents Chemother 1986; 29: 645–8
- Roholt K. Pharmacokinetic studies with mecillinam and pivmecillinam. J Antimicrob Chemother 1977; 3: 71–81
- Blaser M J., Berkowitz I D., LaForce F M., Cravens J, Reller L B., Wang W-L. Campylobacter enteritis: clinical and epidemiological features. Ann Intern Med 1979; 91: 179–85
- Manual of clinical microbiology. 4th ed., E H. Lennette, A Balows, W J. Hausler, Jr, H J. Shadomy. American Society for Microbiology, Washington, DC 1985
- Edwards P R., Ewing W H. Edwards and Ewing's identification of Enterobacteriaceae. 4th ed. Elsevier Science Publishing Co, New York 1986
- Bauer A W., Kirby W MM, Sherris J C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493–6
- Frost J A., Rowe B, Vandepitte J, Threlfall E J. Plasmid characterisation in the investigation of an epidemic caused by multiply resistant Shigella dysenteriae type 1 in Central Africa. Lancet 1981; 2: 1074–6
- Hansson H B., Walder M, Juhlin I. Susceptibility of shigellae to mecillinam, nalidixic acid, trimethoprim, and five other antimicrobial agents. Antimicrob Agents Chemother 1981; 19: 271–3
- Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991; 118: 627–32
- Mitra A K., Kabir I, Hossain M A. Pivmecillinam-resistant Shigella dysenteriae type 1 infection in Bangladesh (letter). Lancet 1990; 335: 461–2